SEC Comment Letter 0000000000-24-000326 to Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Panbela Therapeutics, Inc. (PBLA) (CIK 0001029125)
Date: Jan. 10, 2024 · CIK: 0001029125 · Accession: 0000000000-24-000326
AI Filing Summary & Sentiment
File numbers found in text: 333-276367
Letter
United States securities and exchange commission logo January 9, 2024 Jennifer K. Simpson, Ph.D., MSN, CRNP Chief Executive Officer Panbela Therapeutics, Inc. 712 Vista Blvd, Suite 305 Waconia, Minnesota 55387 Re:Panbela Therapeutics, Inc. Registration Statement on Form S-1 Filed January 4, 2024 File No. 333-276367 Dear Jennifer K. Simpson: We have conducted a limited review of your registration statement and have the following comments. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe a comment applies to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to this letter, we may have additional comments. Registration Statement on Form S-1 Cover Page 1.Please revise the headings on your cover page to quantify the volume of the Class E, Class F and Pre-Funded Warrants you will be registering. 2.We note your disclosure that you have engaged Roth Capital Partners to act as your placement agent in a best efforts offering. Please revise your cover page to disclose the termination date of the offering. See Item 501(b)(8)(iii) of Regulation S-K. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate time for us to review any amendment prior to the requested effective date of the registration
FirstName LastNameJennifer K. Simpson, Ph.D., MSN, CRNP Comapany NamePanbela Therapeutics, Inc. January 9, 2024 Page 2 FirstName LastName Jennifer K. Simpson, Ph.D., MSN, CRNP Panbela Therapeutics, Inc. January 9, 2024 Page 2 statement. Please contact Tim Buchmiller at 202-551-3635 or Laura Crotty at 202-551-7614 with any other questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Joshua L. Colburn, Esq.
Show Raw Text
United States securities and exchange commission logo
January 9, 2024
Jennifer K. Simpson, Ph.D., MSN, CRNP
Chief Executive Officer
Panbela Therapeutics, Inc.
712 Vista Blvd, Suite 305
Waconia, Minnesota 55387
Re:Panbela Therapeutics, Inc.
Registration Statement on Form S-1
Filed January 4, 2024
File No. 333-276367
Dear Jennifer K. Simpson:
We have conducted a limited review of your registration statement and have the
following comments.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe a comment applies to your facts and circumstances
or do not believe an amendment is appropriate, please tell us why in your response.
After reviewing any amendment to your registration statement and the information you
provide in response to this letter, we may have additional comments.
Registration Statement on Form S-1
Cover Page
1.Please revise the headings on your cover page to quantify the volume of the Class E, Class
F and Pre-Funded Warrants you will be registering.
2.We note your disclosure that you have engaged Roth Capital Partners to act as your
placement agent in a best efforts offering. Please revise your cover page to disclose the
termination date of the offering. See Item 501(b)(8)(iii) of Regulation S-K.
We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
Refer to Rules 460 and 461 regarding requests for acceleration. Please allow adequate
time for us to review any amendment prior to the requested effective date of the registration
FirstName LastNameJennifer K. Simpson, Ph.D., MSN, CRNP
Comapany NamePanbela Therapeutics, Inc.
January 9, 2024 Page 2
FirstName LastName
Jennifer K. Simpson, Ph.D., MSN, CRNP
Panbela Therapeutics, Inc.
January 9, 2024
Page 2
statement.
Please contact Tim Buchmiller at 202-551-3635 or Laura Crotty at 202-551-7614 with
any other questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Joshua L. Colburn, Esq.